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Objective: Low-dose-ratebrachytherapy (LDR-BT) in local-
ized prostate cancer is available since 15 years in Italy. We
realized the first national multicentre and multidisciplinary
data collection to evaluate LDR-BT practice, given as
monotherapy, and outcome in terms of biochemical failure.
Methods: Between May 1998 and December 2011,
2237 patients with early-stage prostate cancer from 11 Italian
communityandacademichospitalswere treatedwith iodine-
125 (125I) or palladium-103 LDR-BT as monotherapy and
followed up for at least 2 years. 125I seeds were implanted in
97.7% of the patients: the mean dose received by 90% of
target volumewas 145Gy; themean target volume receiving
100%ofprescribeddose(V100)was91.1%.Biochemical failure-
free survival (BFFS), disease-specific survival (DSS) and
overall survival (OS) were estimated using Kaplan–Meier
method.Log-rank test andmultivariableCox regressionwere
usedtoevaluatetherelationshipofcovariateswithoutcomes.
Results: Median follow-up time was 65 months. 5- and
7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%,
and 92 and 88%, respectively. At multivariate analysis,
the National Comprehensive Cancer Network score
(p,0.0001) and V100 (p50.09) were correlated with
BFFS, with V100 effect significantly different between
patients at low risk and those at intermediate/high risk
(p50.04). Short follow-up and lack of toxicity data
represent the main limitations for a global evaluation of
LDR-BT.
Conclusion: This first multicentre Italian report confirms
LDR-BT as an excellent curative modality for low-/
intermediate-risk prostate cancer.
Advances in knowledge: Multidisciplinary teams may
help to select adequately patients to be treated with
brachytherapy, with a direct impact on the implant quality
and, possibly, on outcome.
INTRODUCTION
Males with localized prostate cancer and indication for curative
treatment are candidates for radical prostatectomy (RP), exter-
nal beam radiotherapy (EBRT) or brachytherapy (BT) depend-
ing on the disease features, patient age, health conditions and
preferences. Few radiation oncology centres in Italy started low-
dose-rate brachytherapy (LDR-BT) at the end of the 1990s and
.4200 patients have been treated with this modality until 2014
in 13 institutes.
Long-term results have demonstrated the efficacy of this treat-
ment modality and this approach is considered as an established
option for low- and intermediate-risk disease.1–4
The aim of the present study was to realize the first Italian
multicentre low-dose-rate prostate BT data collection, reporting
the selection criteria, implant parameters and biochemical out-
come of patients treated in Italy using this modality and com-
paring them with other multi-institutional reports.5–10
For this purpose, 11 Italian community and academic hospitals
(Figure 1) pooled their data to generate a large patient cohort
involving 2237 patients treated with LDR-BT over a period of
14 years, now with a minimum follow-up of 2 years.
METHODS AND MATERIALS
Study design and organization
All the 13 Italian centres performing LDR-BT for prostate cancer
were contacted and invited to this study. It is a retrospective
multicentre cohort study and consists in a centralized collection
and analysis of the clinical and physical parameters of patients
who underwent LDR-BT for prostate cancer. The inclusion
criteria were as follows: (1) LDR-BT for early prostate cancer;
(2) implant performed between May 1998 and December 2011;
(3) LDR-BT given as monotherapy; (4) written informed con-
sent and (5) follow-up of minimum of 2 years.
All participating centres were instructed to use the same data-
base previously designed by expert personnel of one centre.
Completely anonymized data collection was centrally co-
ordinated by the epidemiology and biostatistics division of an-
other centre.
Database structure, data collection instruments, manuals and
processes, especially for the handling of missing data, were
standardized and shared by all investigators. Data entry was
performed locally by each local data management unit and sent
to the coordinating centre for data cleaning and validation.
For the purpose of this study, the following parameters have
been collected: age, pre-treatment prostate-specific antigen
(PSA) level, Gleason score, T-stage, National Comprehensive
Cancer Network (NCCN) risk group classification,11 pre-
implant prostate volume, pre-implant androgen deprivation
(AD) therapy, implant date, radioactive isotope, prescription
dose, post-implant dose received by 90% of target volume (D90),
post-implant target volume that received 100% of the prescribed
dose (V100), last follow-up date, last post-implant PSA dosage,
biochemical failure (BF) and vital status data.
No formal ethics review committee was involved for this ret-
rospective anonymized data collection; all patients gave their
written informed consent for LDR-BT, and each step of patient
care followed the basic principles outlined in the Declaration of
Helsinki.
Statistical analysis
The analyses were performed with SAS statistical software for
Windows 9.2 (SAS Institute Inc., Cary, NC).12 Continuous data
were expressed as mean 6 standard deviation if normally dis-
tributed and as median and range or interquartile range (IQR)
otherwise; categorical variables were expressed as percentages.
Patients were stratified according to the NCCN risk group
classification into low-, intermediate- and high-risk groups: “low
risk” was defined as PSA level #10 ngml21, Gleason score #6
and Stage T1–T2a; “intermediate risk” was defined as one or
more risk factors: PSA level 10–20 ngml21, Gleason score 7 and
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Stage T2b–T2c; and “high risk” was defined as one or more risk
factors: PSA .20 ngml21, Gleason score .7 and Stage $T3a.11
BF was considered according to the Phoenix definition (PSA
nadir plus 2 ngml21).13 Biochemical failure-free survival (BFFS)
was calculated from the date of implantation to the date of event
or latest follow-up.
Disease-specific survival and overall survival (OS) were calculated
from date of implantation to date of death or latest follow-up.
Survival experience was represented by the Kaplan–Meier ap-
proach, with differences between groups evaluated by the log-rank
test. Multivariable Cox regression model including NCCN risk
group classification, D90, post-implant V100, neoadjuvant AD
therapy, patient age and prostatic volume at implant was used to
evaluate the relationship of covariates with BFFS. All tests were
two-sided.
RESULTS
11 Italian institutions provided clinical data of consecutive
patients treated with LDR-BT for clinically localized prostate
cancer. Between May 1998 and 31 December 2013, 2706 con-
secutive patients were treated. However, 380 patients did not
reach a minimum follow-up of 2 years and an additional
89 patients were treated with a combination of LDR-BT and
EBRT. All these patients were excluded. The last patient with at
least 2 years of follow-up was treated on 27 December 2011 and
the final number of included patients was 2237 (Figure 1).
Figure 1. CONSORT flow diagram of the study. EBRT, external beam radiotherapy; LDR-BT, low-dose-rate brachytherapy.
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Patient characteristics
The mean age of patients was 676 7 years with a median pre-
treatment PSA value of 6.5 ngml21 (PSA range: 0.64–96) and
the mean pre-implant prostate volume (including the effect of
an eventual neoadjuvant AD) of 35.76 9.7 cm3.
According to the NCCN risk group classification, 66.4% (1485/
2237) of the patients were classified as belonging to low-risk
group, 26.0% (582/2237) patients as belonging to intermediate-
risk group and 1.8% (41/2237) patients as belonging to high-risk
group, while 5.8% (129/2237) patients could not be un-
equivocally categorized (Table 1).
Table 2 reports the proportion of patients who had received AD
before BTwithin each NCCN risk group. The higher the NCCN
risk classification, the greater the proportion of patients with
a history of AD before LDR-BT implantation.
Treatment procedures
A similar BT protocol was carried out by all 11 institutions. In all
the institutions, a multidisciplinary uro-oncologic team, caring
also for patients with prostate cancer, was active.
Seed implantation was performed using a transperineal approach
with transrectal ultrasound guidance. The radioactive isotope
implanted was iodine-125 (125I) in most of the cases and
palladium-103 (103Pd) in some of the most dated cases. The
intended prescribed dose was changed depending on the isotope
used (145Gy and 135Gy using 125I and 103Pd, respectively). Dose
was prescribed to the prostate volume as defined at ultrasound
images and a choice of a margin around prostate was operator
dependent, usually ranging between 3 and 5mm to account for
possible extraprostatic extension and for seed release uncertainties.
Neoadjuvant AD therapy with an antiandrogen and/or a lutei-
nizing hormone-releasing hormone analogue was prescribed
mainly for volume reduction in patients with large prostate for
a short period (3–6 months; median 4 months).14
Post-implant CT dosimetry was performed within 1 month
(mainly on Day 30) of implantation.15
Patients were followed up every 3–6 months with PSA assays for
the first 2 years and every 6–12 months thereafter.
Treatment data
125I and 103Pd seeds were implanted in 2185 (97.7%) patients
and 52 (2.3%) patients, respectively. The mean D90 was 146Gy
(628Gy) for patients with 125I seeds and 130Gy (624Gy) for
patients with 103Pd seeds; the V100 was 91.2% (67.4%) for
patients with 125I seeds and 87.9% (68.1%) for patients with
103Pd implants (Table 3).
Outcome data
The overall median follow-up time was 65 months (IQR:
42–93 months). 204 deaths were recorded. 172 patients died
without any BF, while 32 males died after a BF. For 26 of them,
the fatal event was related to metastatic disease progression
(Table 4). The 3-, 5- and 7-year OS rates were 96.7, 94.0 and
Table 1. Baseline characteristics
Age, categorical (number of patients) (%)
,50 years 11 (0.5)
50–59 years 320 (14.3)
60–69 years 966 (43.2)
70–79 years 915 (40.9)
$80 years 25 (1.1)
Age, continuous (years)
Mean (SD) 67 (7)
Median (range) 68 (39–86)
NCCN risk group classification (number of patients) (%)
Low risk 1485 (66.4)
Intermediate risk 582 (26.0)
High risk 41 (1.8)
N/A 129 (5.8)
Gleason score (number of patients) (%)
#6 1861 (83.2)
7 271 (12.1)
.7 28 (1.3)
N/A 77 (3.4)
T stagea (number of patients) (%)
T1 (a, b, c) 1597 (71.4)
T2–T2a 354 (15.8)
T2b–T2c 141 (6.3)
T3 (a, b, c) 1 (0.1)
N/A 144 (6.4)
PSA category at entry (number of patients) (%)
#10 ngml21 1937 (86.6)
10–20 ngml21 260 (11.6)
.20 ngml21 14 (0.6)
N/A 26 (1.2)
PSA at entry (ngml21)
Median (range) 6.5 (0.64–96)
Neoadjuvant AD therapy (number of patients) (%)
No 1099 (49.1)
Yes 882 (39.4)
N/A 256 (11.5)
Pre-implant prostate volume (cm3)
N 2115
Mean (SD) 35.7 (9.7)
Median (range) 35.0 (11.5–83.5)
AD, androgen deprivation; N/A, not available; NCCN, National
Comprehensive Cancer Network; PSA, prostate-specific antigen; SD,
standard deviation.
aAmerican Joint Committee on Cancer staging, 7th edn, 2009.
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89.2%, respectively, and the 3-, 5- and 7-year disease-specific
survival rates were 99.7, 99.5 and 98.4%, respectively (Figure 2).
207 patients experienced a BF and 175 of them were alive at the
last follow-up. The median time elapsed between LDR-BT im-
plantation and occurrence of BF was approximately 42 months
(IQR: 24–64 months) (Table 4). The 3-, 5- and 7-year BFFS was
95.7, 91.9 and 88.5%, respectively (Figure 3 and Table 5).
Multivariate analysis showed that BFFS was significantly higher
among patients in the low-risk group (p, 0.0001) and close to
be significantly higher among those with V100$ 90% (p5 0.09).
In particular, after inclusion of the interaction term of the two
factors in the model, we found that V100$ 90% increased BFFS
only in the subset of patients in the low-risk group [relative
risk5 0.53 (95% confidence interval: 0.33–0.84], while no effect
was found among the patients in the intermediate-/high-risk
group [relative risk5 1.09 (95% confidence interval: 0.69–1.74);
p5 0.04] for the interaction term. No other factor exhibited
significant influence on BFFS (Table 5).
To check for potential prognostic factors on OS, we performed
univariate and multivariate analyses. The intermediate-/high-
risk group showed the worst OS compared with the low-risk
group (p5 0.04 and p5 0.07, respectively); OS was also worst in
elderly patients (p, 0.0001) (Table 6).
DISCUSSION
This early report is a retrospective multicentre cohort study and
gives an efficient picture of the practice of BT in Italy, including
Table 2. Neoadjuvant androgen deprivation (AD) therapy and risk group classification
Neoadjuvant AD
therapy
NCCN risk group classification
Low Intermediate High N/A Total
Number of
patients (%)
Number of
patients (%)
Number of
patients (%)
Number of
patients (%)
Total number of
patients (%)
No 795 (58.0) 248 (48.1) 8 (36.4) 48 (66.7) 1099 (55.5)
Yes 576 (42.0) 268 (51.9) 14 (63.6) 24 (33.3) 882 (44.5)
Total with AD therapy
information
1371 516 22 72 1981
N/A 114 66 19 57 256
Total 1485 582 41 129 2237
N/A, not available; NCCN, National Comprehensive Cancer Network.
Table 3. Treatment modality and dosimetry
Dosimetry
Radioactive isotope Total
125I 103Pd
N5 2185 N5 52 N5 2237
D90 (Gy)
N 2173 50 2223
Mean (SD) 146 (28) 130 (24) 145 (28)
Median (IQR) 149 (124–167) 134 (123–146) 149 (124–166)
D90 (% of the prescribed dose)
N 2173 50 2223
Mean (SD) 1.01 (0.2) 0.97 (0.17) 1.01 (0.2)
Median (IQR) 1.03 (0.86–1.15) 0.99 (0.91–1.08) 1.03 (0.86–1.15)
V100 (%)
N 2172 52 2224
Mean (SD) 91.2 (7.4) 87.9 (8.1) 91.1 (7.4)
Median (IQR) 93 (89–96) 90 (87–93) 93 (89–96)
125I, iodine-125; 103Pd, palladium-103; D90, dose received by 90% of target volume; IQR, interquartile range; SD, standard deviation; V100, target volume
receiving 100% of the prescribed dose.
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11/13 centres practising it and most of the patients treated in
Italy. To the best of our knowledge, this is the largest LDR-BT
European series ever reported.
Our results indicate that an implant of good quality, both for
case selection and post-implant dosimetric parameters, has
been obtained in most patients. The selection criteria show
adherence to accepted guidelines based on the European So-
ciety for Radiotherapy and Oncology–European Association of
Urology–European Organization for Research and Treatment
of Cancer recommendations,16,17 with implant being used for
66.4% of cases in the low-risk group and 26.0% of cases in the
intermediate-risk group, with a prescribed dose of 145 Gy for
I125; a short AD therapy, was given to 39.4% of patients
(mainly for downsizing). Post-implant data show a mean D90
of 146 Gy and a mean V100 value of 91.2% for patients with I
125
implants.
The BFFS rates at 5 and 7 years were estimated to be 91.9% and
88.5% for the whole group, respectively, with an event rate of
6.3% (93/1485) in the low-risk group, 15.6% (91/582) in the
intermediate-risk group and 24.4% (10/41) in the high-risk
group, respectively (p, 0.0001). Our results, in agreement with
other multi-institutional reports5–8,10 and with two recently
published monoinstitutional series,18,19 indicate that
LDR-BT with permanent implant as monotherapy is an
adequate modality for the radical treatment of low- and
intermediate-risk prostate cancer. Only 89 patients with
unfavourable factors were treated combining BT and EBRT and
were excluded in the present analysis. Durable cancer control was
reported with the BT and EBRT combination in these patients,20
but there may be an increased toxicity,21 and LDR-BT alone
can produce excellent biochemical control for low- as well as
intermediate-risk disease.4
Approximately 40% of patients in the present series had pre-
viously undergone neoadjuvant AD therapy for 3–6 months.
This short period of AD did not impact on BFFS. This is in
agreement with other reports.10,22
Table 4. Events
Outcomes N (%)
Follow-up duration (months)a (%)
Mean (SD) 69 (34)
Median (IQR) 65 (42–93)
Vital status (number of patients) (%)
Alive 2033 (90.9)
Dead 204 (9.4)
Death without BF 172
#24 months 33
.24 months 139
Death after BF 32
#24 months 1
.24 months 31
Of whom owing to prostatic cancer 26
BF (number of patients) (%)
No 2030 (90.7)
Yes 207 (9.3)
Alive at the last follow-up 175
Death after BF 32
Time to BF (months)a
N 207
Mean (SD) 48 (29)
Median (IQR) 42 (24–64)
BF, biochemical failure; IQR, interquartile range; SD, standard deviation.
aFrom date of low-dose-rate brachytherapy implantation.
Figure 2. Kaplan–Meier analysis of overall survival (OS) and
disease-specific survival (DSS) with 95% confidence interval
(CI). Pts, patients.
Figure 3. Kaplan–Meier analysis of biochemical failure-free
survival (BFFS) with 95% confidence interval (CI). Pts, patients.
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Table 5. Biochemical failure-free survival (BFFS) in subgroups
Subgroups Total Events
Univariate analysis Multivariate analysisc
3-year
BFFS
(%)
5-year
BFFS
(%)
7-year
BFFS
(%)
p-valuea RR (95% CI) p-valueb
All patientsb 2237 207 95.7 91.9 88.5
NCCN risk group classification
Low risk 1485 93 97.0 94.8 92.8
,0.001
1
Intermediate risk 582 91 93.8 86.0 78.4 2.60 (1.93–3.51) ,0.0001
High risk 41 10 78.9 73.0 73.0 3.02 (1.38–6.60) 0.006
V100 (%)
,90% 642 77 95.3 90.1 86.4
0.03
1
$90% 1582 128 96.0 92.8 89.5 0.76 (0.55–1.04) 0.09
D90 (% of the prescribed dose)
,90% 668 62 95.8 91.1 89.1
0.49
1
$90% 1555 143 95.8 92.3 88.5 1.01 (0.72–1.42) 0.93
Neoadjuvant AD therapy
No 1099 96 96.3 92.6 89.2
0.59
1
Yes 882 80 95.8 92.0 89.1 0.79 (0.58–1.07) 0.13
Radioactive isotope
125I 2185 202 95.7 91.9 85.5
0.45
1
103Pd 52 5 96.1 91.7 89.1 0.92 (0.37–2.25) 0.85
Age (years)
,55 102 7 96.9 95.7 90.9
0.42
1
55–64 637 56 94.6 93.4 90.8 1.31 (0.59–2.88) 0.51
65–74 1187 112 96.3 91.5 88.0 1.38 (0.64–2.97) 0.42
$75 311 32 95.2 88.7 84.7 1.50 (0.65–3.46) 0.34
Interactionsd
NCCN risk
group–V100
$90% vs ,90%
(low-risk group)
0.53 (0.33–0.84)
0.04$90% vs ,90%
(intermediate-/
high-risk group)
1.09 (0.69–1.74)
NCCN risk group–neoadjuvant AD therapy
AD therapy vs no
AD therapy
(low-risk group)
0.56 (0.35–0.89)
0.07AD therapy vs no
AD therapy
(intermediate-/
high-risk group)
1.09 (0.69–1.71)
(Continued)
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The impact of post-implant dosimetric parameters on BFFS in
multi-institutional studies is not univocal. Zelefsky et al5 noted
a significant impact of D90 on BFFS after a median follow-up of
63 months. These data are reinforced by Stone et al.9 Contrarily,
no post-implant dosimetric factors predicted for biochemical
control in a UK multi-institutional series with a median
follow-up of 21 months.7 Morris et al8 reported results of the
British Columbia Cancer Agency BT database after a median
follow-up of 7.5 years: D90 values of ,130Gy were predictive of
an increased risk of recurrence but only for the subset of males
who did not receive AD therapy.10 In our cohort, post-implant
V100, but not D90, impacted significantly on biochemical
control, in spite of a strict correlation between them. The 5-
and 7-year BFFS was 90.1 vs 92.8% and 86.4 vs 89.5% for V100
,90% vs $90% (p5 0.03), whereas the difference was not
statistically significant for D90,130 Gy or $130 Gy
(p5 0.49). These results were confirmed after multivariate
analysis (p5 0.09 and p5 0.93, respectively). We think that
this may be a consequence of the preponderance of good-
quality implants in the present series: only 30% (668/2237) of
patients had a D90 ,90% of the prescribed dose and median
D90 was 149 Gy for patients with I
125 seeds. Furthermore, the
evaluation of post-implant dosimetric parameters and
their impact on BFFS may be less robust owing to differences
in post-planning CT timing and interpretation among dif-
ferent institutions;23 the average D90 in our cohort had
a standard deviation of 28 Gy. A more standard approach
to volume delineation should be an important aspect of
quality assurance in prostate BT.17 As stated by Morris et al10
in their study, “dose metrics are not equivalent to oncologic
end points and must be calibrated against disease-free sur-
vival using biochemical and clinical end points for each
institution”.
Prostate BT seems comparable with both EBRT and RP.4,24
No randomized trials are available and many comparative
outcome studies are largely single-centre studies with
limited generalizability, and a population-based study pro-
vides the best outcome data. This report details PSA and OS
outcomes after LDR-BT in a large and consecutive
population-based cohort of patients and together with other
multi-institutional studies,5–8,10 it might give more gener-
alizable data.
There are several limitations of our study. Firstly, data were
collected retrospectively. Not all the institutions provided
sufficient data and not all the information we had planned
to get were actually available in the local databases. The lack
of important covariates (comorbidity, smoking history,
centre-specific policy regarding frequency of PSA testing
during all over the follow-up and site of clinical failure)
results in a substantial loss of strength of our multivariate
and subgroup analyses. Secondly, the median follow-up was
only of 65 months; this time is too short for a substantial
evaluation of the real biochemical outcome after a radical
treatment. This relatively short follow-up duration and the
high rate of patients lost to long-term follow-up produce
a loss of power for the 10-year survival estimates. For this-
reason, in our analysis, we showed estimates at earlier
time points.
Thirdly, although these LDR-BT results are encouraging,
our series may include the selection bias, especially in
the intermediate-risk group (selection of more favourable
cases). Therefore, direct comparison of our findings in the
intermediate-risk patients with those obtained with other
treatment modalities such as EBRT and RP should be per-
formed with caution.
Finally, our study does not provide any data on BT side effects.
Evaluation of treatment sequelae in a retrospective multi-
institutional study is difficult and uncertain. Still, BT compli-
cations and their impact on quality of life in the series of
a participating centre have been reported.25
Table 5. (Continued)
Subgroups Total Events
Univariate analysis Multivariate analysisc
3-year
BFFS
(%)
5-year
BFFS
(%)
7-year
BFFS
(%)
p-valuea RR (95% CI) p-valueb
NCCN risk group–radioactive isotope
103Pd vs 125I
(low-risk group)
0.43 (0.10–1.76)
0.10103Pd vs 125I
(intermediate-/
high-risk group)
2.34 (0.72–7.61)
125I, iodine-125; 103Pd, palladium-103; AD, androgen deprivation; CI, confidence interval; D90, dose received by 90% of target volume; NCCN, National
Comprehensive Cancer Network; RR, relative risk; V100; target volume receiving 100% of prescribed dose.
The sum of the number of patients among levels of a variable could be not equal to the total number of patients (N52237).
The “not available (N/A)” subgroups, although included both in univariate and multivariate models, have not been shown in this table.
aLog-rank test for univariate analysis.
bWald test from Cox regression multivariate model.
cIncludes NCCN risk group, V100, D90, neoadjuvant AD therapy, radioactive isotope, age and prostatic volume at implantation.
dIncludes the same variables of c plus the interaction term.
BJR Fellin et al
8 of 11 birpublications.org/bjr Br J Radiol;89:20150981
The retrospective character of our report carries the well-known
risks of missing data and selection bias. However, our report
provides information on BT results in nearly all patients who
underwent LDR-BT in Italy. Reporting these data is now par-
ticularly crucial for a realistic comparison with other modalities
of radical treatment, such as new surgery and radiotherapy
techniques or radiotherapy fractionation schemes, which are
rapidly spreading in the community,26,27 despite a less mature
evidence of efficacy and perhaps a higher cost.
CONCLUSION
In conclusion, the findings in this largest European series are in
agreement with those previously reported in literature and
confirm that LDR-BT is an excellent curative modality for low-
and intermediate-risk prostate cancer. The work of the multi-
disciplinary team involved in the treatment of patients with
prostate cancer may help to select adequately patients to be
treated with BT and this may impact on the implant quality and
possibly on outcome.
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Table 6. Overall survival (OS) in subgroups
Subgroups Total Events
Univariate analysis Multivariate analysisc
3-year
OSc (%)
5-year
OS (%)
7-year
OS (%)
p-valuea RR (95% CI) p-valueb
All patientsb 2237 204 96.7 94.0 89.0
NCCN risk group classification
Low risk 1485 117 97.2 94.7 91.1
0.001
1
Intermediate risk 582 69 95.3 91.9 85.7 1.37 (1.01–1.87) 0.04
High risk 41 8 92.9 89.6 77.1 2.12 (0.94–4.76) 0.07
V100 (%)
,90% 642 54 97.6 94.7 90.1
0.16
1
$90% 1582 146 96.4 93.8 89.1 1.30 (0.92–1.85) 0.14
D90 (% of the prescribed dose)
,90% 668 50 96.6 93.9 89.9
0.43
1
$90% 1555 150 96.9 94.2 89.2 1.22 (0.85–1.76) 0.28
Neoadjuvant AD therapy
No 1099 89 97.2 94.0 89.7
0.30
1
Yes 882 99 95.9 93.3 88.6 0.98 (0.73–1.32) 0.90
Radioactive isotope
125I 2185 197 96.6 94.1 89.3
0.96
1
103Pd 52 7 98.0 91.6 86.6 1.29 (0.60–2.78) 0.51
Age (years)
,55 102 1 99.0 99.0 99.0
,0.0001
0.05 (0.01–0.39) 0.001
55–64 637 38 97.9 96.5 92.7 0.33 (0.21–0.52) ,0.0001
65–74 1187 117 96.0 92.9 88.4 0.55 (0.39–0.77) ,0.001
$75 311 48 95.9 91.2 81.5 1 –
125I, iodine-125; 103Pd, palladium-103; AD, androgen deprivation; CI, confidence interval; D90, dose received by 90% of target volume; NCCN, National
Comprehensive Cancer Network; RR, relative risk; V100, target volume receiving 100% of prescribed dose.
The sum of the number of patients among levels of a variable could be not equal to the total number of patients (N52237).
The “not available (N/A)” subgroups, although included both in univariate and multivariate models, have not been shown in this table.
aLog-rank test for univariate analysis.
bWald test from Cox regression multivariate model.
cIncludes NCCN risk group, V100, D90, neoadjuvant AD therapy, radioactive isotope, age and prostatic volume at implantation.
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